trpv4 (ProSci Incorporated)
ProSci Incorporated is a verified supplier 
ProSci Incorporated manufactures this product 
91
Structured Review
ProSci Incorporated
trpv4
Trpv4, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trpv4/product/ProSci Incorporated
Average 91 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Trpv4, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trpv4/product/ProSci Incorporated
Average 91 stars, based on 1 article reviews
Price from $9.99 to $1999.99
trpv4 - by Bioz Stars,
2023-06
91/100 stars
Images
1) Product Images from "VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions"
Article Title: VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions
Journal: Investigative Ophthalmology & Visual Science
doi: 10.1167/iovs.61.11.35
Figure Legend Snippet: Antibodies Used for Western Blotting and Immunofluorescence
Techniques Used: Western Blot
Figure Legend Snippet: Effect of VEGF-B on TRPV4 expression and functionality under oxidative stress. ( A – C ) QMMuC-1 cells were treated with 4-HNE (10 µM) with or without recombinant VEGF-B (100 ng/mL) for 24 hours. The expression of TRPV4 was examined by immunofluorescence staining ( A, B ) and Western Blot ( C ). ( A ) Representative image of TRPV4 ( green ) and phalloidin ( red ) in untreated control, 4-HNE treated and 4-HNE + recombinant VEGF-B (100 ng/mL) treated QMMuC-1 cells. Arrow in control indicates cluster aggregation of TRPV4. Arrows in 4-HNE–treated group indicates contracted cell body. ( B ) Quantitative analysis of different types of TRPV4-expressing QMMuC-1 cells (A, spread cell with evenly distributed TRPV4; B, spread cell with aggregated or uneven TRPV4 expression; C, contracted cell with aggregated TRPV4 expression). **** P < 0.001; n = 4 wells per experiment. Two-way ANOVA followed by Bonferroni post hoc test. ( C ) Western Blot of TRPV4 expression on 4-HNE–treated QMMuC-1 cells with/without recombinant VEGF-B, n = 6–7. ( D and E ) Effect of TRPV4 and VEGF-B on intracellular Ca 2+ concentration in 4-HNE–treated QMMuC-1 cells and its representative plots ( D ). Intracellular Ca 2+ levels were measured using the FlexStation. The y -axis was the 340 nm/380 nm fluorescence ratio (ΔR340 nm/380 nm). ( D and E ) TRPV4 agonist GSK101 (100 nM) alone did not elicit a measurable calcium response in QMMuC-1 cells. A 24 hours 4-HNE (10 µM) treatment significantly increased the GSK101-evoked response, which was fully blocked by the TRPV4 antagonist HC06 (10 µM) and by recombinant VEGF-B (100 ng/mL). Mean ± SD, n = 4–8 **** P < 0.001; one-way ANOVA followed by Newmann-Keuls post hoc test. All experiments were performed at least twice.
Techniques Used: Expressing, Recombinant, Immunofluorescence, Staining, Western Blot, Concentration Assay, Fluorescence